Loading financial data...

Milestone Pharmaceuticals Inc. (MIST) Financial Statements | Global Financial Data

Milestone Pharmaceuticals Inc.

MISTSEC EDGAR

Pharmaceutical Preparations(A8)CIK: 1408443

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$31.1M	$39.8M	$38.7M	$34.5M	$42.0M
Operating Income (Loss)	-$61.1M	-$59.6M	-$43.1M	-$50.7M	-$57.9M
Interest Expense	—	$2.6M	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$59.7M	-$58.4M	-$42.9M	-$50.0M	—
Income Tax Expense (Benefit)	—	—	—	-$17.0K	-$56.0K
Net Income (Loss) Attributable to Parent	-$59.7M	-$58.4M	-$42.9M	-$50.0M	-$55.2M
Earnings Per Share, Basic	-$1.39	-$1.38	-$1.02	-$1.70	—
Earnings Per Share, Diluted	-$1.39	-$1.38	—	-$1.70	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$75.2M	$74.5M	$119.8M	$150.0M	$123.4M
Assets, Current	$73.0M	$71.8M	$118.9M	$148.7M	$122.5M
Cash and Cash Equivalents, at Carrying Value	$13.8M	$7.6M	$114.1M	$72.3M	$119.8M
Liabilities	$58.5M	$8.1M	$7.2M	$6.9M	$8.5M
Liabilities, Current	$7.2M	$6.1M	$6.8M	$6.2M	$8.3M
Long-term Debt	$49.8M	$49.8M	—	—	—
Stockholders' Equity Attributable to Parent	$66.3M	$112.6M	$143.1M	$114.9M	$83.5M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$46.4M	-$52.5M	-$33.2M	-$50.7M	-$51.2M
Net Cash Provided by (Used in) Investing Activities	$4.8M	-$57.1M	$70.0M	-$70.0M	-$384.0K
Net Cash Provided by (Used in) Financing Activities	$47.8M	$3.1M	$5.1M	$73.2M	$85.4M
Payments to Acquire Property, Plant, and Equipment	$112.0K	$272.0K	$272.0K	—	$413.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)